Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
stockaudit- Nice.. and positive they were done professionally. Thanks
Chump
Another must read, top poster-CCR5 , Cancers , Leronlimab....
1.) CCR5 makes cancers cells metastasize ...
........A.) By calcium channel signalling on CCR5 on cancer cells , witch is important to produce metastasis.
........B.) CCR5 makes tumors more aggressive , CCR5 center cells cluster together in a different way witch enables the cancer cells to metastasize ...(Thank you Trding).
.........C. ) once cancer cells enter to bloodstream and ( and thus become ) CTC, being CCR5 + guides them to the most dangerous and deadly possible sites : Brain , bones , other organs , ..(.Thank you Trding.)
Leronlimab block all this...
Papers:
https://content.equisolve.net/_5dde3bf0adc368...breast.pdf
https://content.equisolve.net/_5dde3bf0adc368...review.pdf
https://content.equisolve.net/_5dde3bf0adc368...ostate.pdf
https://cancerres.aacrjournals.org/content/ca...7.full.pdf
2.) CCR5 activates DNA mechanism....
...........cancer cells recuperate much faster after chemotherapy , becoming resistant to treatment ,
Leronlimab is blocking that.
Papers:
https://content.equisolve.net/_5dde3bf0adc368...R.full.pdf
https://www.cell.com/stem-cell-reports/pdf/S2...0145-6.pdf
3.) Regulate body anti-tumor response ..
...........A. ) there is polarization of macrophages with CCR5 inhibitors.
process by witch macrophages adopt different functional programs..
M0--uncommitted macrophages ..
M1--classically activated , produce pro-inflammatory process and irritation of immune system , important in the host defense against pathogens .
M2--alternatively activated, turning on constructive process, like wound healing , producing anti-inflammatory cytokines.
And all this help to produce necrosis of tumors.
............B. ) From Dr Patterson we also know that CCR5 is expressed on the population of immune cells call T regulatory cells witch inhibits response to cancers .
Papers:
https://www.cell.com/cancer-cell/pdf/S1535-61...0102-7.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...-01477.pdf
https://www.frontiersin.org/articles/10.3389/...02629/full
4.) Leronlimab inhibits angiogenesis
Recently we also learned from Dr Lindner pre-clinical study in colon cancer that Leronlimab inhibits angiogenesis , and is working on solid tumors with both high and low CCR5 expression..
Papers:
https://www.ncbi.nlm.nih.gov/pubmed/25330803
https://academic.oup.com/carcin/article/36/1/104/376718
https://www.cell.com/stem-cell-reports/pdf/S2...0145-6.pdf
https://www.cytodyn.com/newsroom/press-releas...of-ccr5-in
5) CCR5 Promotes Cancer Recurrance
Paper:
https://elifesciences.org/articles/43653
Node-Negative Overall Survival with ccr5 from Pestell paper Figure 1B
https://content.equisolve.net/_5dde3bf0adc368...R.full.pdf
1445403104_nodeneg.jpg
Chump
Another poster- To add to that, the FDA just approved that plasma/blood device that is meant to address similar issues that Leronlimab addresses by reducing cytokines and other inflammatory markers. I’m probably butchering the device’s actual details but the point i want to make is that it seems the FDA and experts around the country/world are coming to the conclusion that addressing the cytokine storm is extremely important.
That’s part of what keeps me optimistic that good things will happen for Cytodyn despite the size of the company and despite what feels like a borderline conspiracy theory level of unawareness/ignorance in major media outlets. I know it’s changing and we want it to go faster because it means more lives will be saved. But I do think it’s moving at light speed for what would normally occur and the evidence and requests from doctors and hospitals the world over will be impossible to ignore much longer if they are ignoring it. I don’t think they are.
https://www.fda.gov/news-events/press-announc...t-covid-19
Chump
Leronlimab mentioned:
https://www.msn.com/en-us/health/medical/meck...r-BB12wsWx
Chump
From another top notched- Our Media Efforts are Working!!!
For those of you who have been emailing/tweeting/posting/commenting as much as I have you can sometimes grow frustrated that our efforts don't often pan out. However, every once in a while there are indications that our efforts are making a difference (i.e. Charles Payne writing back or reporters thanking us for sending additional info). Here's another small example...
From NY Times Opinion Piece (What You're Saying section at the bottom)
https://www.nytimes.com/2020/04/09/opinion/wa...curve.html
"Readers wrote in to note two other potentially promising drugs that are undergoing clinical trials: Leronlimab, a monoclonal antibody developed to treat H.I.V., and recombinant interferon alfa-2b, a protein that functions as an immune system messenger."
Our efforts, no matter how seemingly small, are working. We are slowly getting on media's radar and hopefully they will start including us in more of their upcoming stories. Thank you to all who take the time to make the world aware. We are a super dedicated bunch who are doing all we can to help get our drug out there so that it can help save more lives!!
Chump
From a top notch poster- The term 'cytokine storm' was termed in 1993 by group in Boston lead by Ferrara in connection with GvHD discussion. Interestingly, another area leronlimab is heavily involved in.
https://www.sciencedirect.com/science/article...159390139J
Cytokine dysregulation as a mechanism of graft versus host disease
Quote:
Graft versus host disease (GVHD) remains the major complication of allogeneic bone marrow transplantation. T cells in the donor bone marrow recognize and react against host alloantigens and thereby initiate GVHD, but the precise mechanisms by which host tissues are damaged remain unclear. Recently, several convergent lines of evidence have suggested that inflammatory cytokines act as mediators of acute GVHD. Most of the clinical manifestations of GVHD may in fact be due to the dysregulated production of cytokines by T cells and other inflammatory cells. The complex interactions among cytokines and their cellular targets suggest that individual cytokines may play an important and distinctive role in the pathophysiology of GVHD. Perturbation of the cytokine network may function as a final common pathway of target organ damage, and the rapid onset of severe, acute GVHD can be considered a ‘cytokine storm.’
Vhump
Post#67697- Is about NAC nothing in it about CYDY. Why is it allowed?
Chump
moneycrew- yes another swing n miss. CYDY going through the roof next week. Chump
Great Dec info on CYDY- Leronlimab (Pro 140) Cliff Notes
What is it?
Leronlimab is a humanized monoclonal antibody targeted against the CCR5 receptor expressed on sub-population of T cells, macrophages, dendritic, eosinophils, microglia, and several cancers types.
Why so many indications?
CCR5 is a chemokine receptor interacting with CCL3, CCL4, and CCL5 (RANTES). CCL5 has an active role in recruiting leukocytes into inflammatory sites, which leronlimab can block. CCR5 also has many other roles: [8,9]
- governing DNA damage repair,
- repolarization of tumor-associated macrophages,
- promoting leukocytes (and metastatic cancer ccr5+ cells) trafficking to the brain, bones, liver and lungs.
What makes it to stand out from than other ccr5 antagonists, HAART, and cancer drugs ?
Low toxicity: Doesn't block natural activity of ccr5 including no hepatotoxicity causing many others to fail their trial safety metric.
No R5 resistance: Competitive inhibitor blocking direct entry to target a specific site on CCR5 that is utilized by HIV vs allosteric in small molecule, which enables resistance development in all small molecule antagonists. With the highest barrier to resistance so far than any other HIV drug, it could be first monotherapy approved drug for HIV.
Weekly dosing/Adherence : Longer half-life (10-14 days) [11,12] allows weekly dosing vs daily pills with others. A large 2013 survey [6,7] of 19 studies showed the association between adherence and specific AEs associated with ART. The same study showed an association with adherence rate and the number of daily pills, 95% adherence from 47% taking one pill daily to 34% with three pills daily. NNRTI, which has traditionally been given as part of core with ART, needs a very high level of adherence to limit mutations Adherence is the second strongest predictor of progression to AIDS after CD4 count. Weekly dosing offers a tremendous advantage in increasing adherence, specifically those in the unmet need category where typically adherence has been the lowest. Note PrEP study will have one arm with monthly dosing as daily pills is one main reason people at risk have stated they avoided PrEP, longer options are better.
Safety: No serious side effects or serious adverse events in over 830 patients. No discontinuing thus far from AEs in mono p2 trial. This makes leronlimab unique among many HIV and cancer drugs. Recognizing overall's drug’s safety FDA has allowed P1 to be skipped in several new indications. This is also helps reduce the added compounding side-effects when using several drugs with HIV or cancer.
Low drug/drug interactions. Leronlimab is eliminated via a saturable, antigen-mediated clearance process [10]. Many other HIV drugs are metabolized by CYP enzymes enabling drug interactions. For example Maraviroc and Rilpivirine are metabolized by CYP3A4, as are many other drugs.
Special Note: HIV has a positive association with NAFLD and cancer, two indications where leronlimab is in p2, which combined with the above benefits, if approved for all indications would make a extremely compelling synergistic treatment for all R5. See end footnote for more details.
Video: Pro 140: How it Combats HIV
Chump
Another CYDY poster-NT this is what I tell my friends about the uniqueness of CYDY + incelDx with regards to requesting emergency approval. They measured immunological markers at day 0 on top of days 3 and 7 and with that can demonstrate without any doubt both immunological restoration occurred (cd8 increase) as well as the reduction in cytokine storm (reduction of il-6 and others) as a result of administration of leronlimab.
If they didn't have Dr. BP's suite of assays I would say requesting emergency approval is a waste of time. But with this combination they have a chance.
Chump
From another CYDY poster- The beauty and poetic sarcasm if this does not end up in an approval is that we (CYDY and IncelLDx) where MEASURING the response of the first patients very carefully (base line, 3, days 7 days).
The counts of Lymphocytes and other blood-work paremeters are there in exquisite (and embarrassing) detail and the patients responses also present and willing to tell the tale (talk to the doctors please !!!).
Can FDA just ignore them ???. Can FDA say that several miracles took place and the T-cell count changes are a fluke ?? Or, not good enough ??. Or, what happened (and keep happening) in several cases maybe will not repeat with some other patients ???.
The possibility of successive unlikely outcomes is ... well, VERY unlikely.
So, FDA, please look at the evidence and stop the carnage now.. Time is of the essence.
Chump
For any CYDY poster from Ihub- IH Admin [Macy] Member Level
Saturday, April 11, 2020 6:38:35 PM
If you believe some illegal activity is occurring then you should address that with the appropriate regulatory or law enforcement agency. iHub has neither the resources nor authority to investigate allegations of illegal activities. If and when a court of competent jurisdiction issues an order that purports to be binding upon iHub we will take it under advisement at that time.
The rules of conduct here are neutral toward investment sentiment and shareholder status. All views are welcome as long as they are on-topic and otherwise comply with the site rules.
So here is a link- https://www.justice.gov/doj/webform/your-message-department-justice
Chump
Samantha Mottet COV survivor- https://losangeles.cbslocal.com/2020/04/10/coronavirus-survivor-leronlimab/
UCLA - This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria because the FDA is short staffed within that capacity. We have all verbal and email approvals to utilize Leronlimab and start the trial treating COV19 patients.
From Dr. Yang:
However, Yang said to all shorting CYDY he believes there is strong evidence to support this theory that "Leronlimab" saved her life.
“In 24 hours, she started requiring less oxygen on the ventilators, and 48 hours after that, she was able to come off the ventilator all together,” Yang said. ‘Then a couple of days after that, she didn’t require any oxygen at all.”
How Chump read it!
19Neener- I do not have face book was sent to me.
Chump
OGREASEARCH- Welcome to CYDY Ihub.
Chump
CYDY from another-The CCR5 receptor is not some systemic poison. The seeming efficacy of leronlimab appears to be a magic key effect that hits the receptor just right with no side effects. Honestly, this appears true but is VERY hard to believe, and I completely understand the initial skepticism by legislative authorities.>>
Chump
Blane- CYDY on one hell of a ride next week up.
Chump
Cydy mentioned:https://www.facebook.com/ScienceNaturePage/ph...63/?type=3
Chump
Blane- CYDY Monday to start.
Chump
From Blullish- He's right. CONGRAT_TO_ALL_LOADING_THE_COVID19_STOCK_$CYDY_BREAKOUT_ALERT
Chump
Bobbyinvest- You are correct it does just that.
Chump
CYDY DD: https://www.cytodyn.com/newsroom/press-releases
Chump
Dr Yang CBS Vegas- CBS Boston- Dr yang-This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria because the FDA is short staffed within that capacity. We have all verbal and email approvals to utilize Leronlimab and start the trial treating COV19 patients.
From Dr. Yang:
However, Yang said to all shorting CYDY he believes there is strong evidence to support this theory that "Leronlimab" saved her life.
“In 24 hours, she started requiring less oxygen on the ventilators, and 48 hours after that, she was able to come off the ventilator all together,” Yang said. ‘Then a couple of days after that, she didn’t require any oxygen at all.”
How Chump read it!
CYDY- video:
CYDY New York-CytoDyn's therapy used to treat New York coronavirus patients shows 'immunological benefits'
Chump
From Novant Health on CYDY-The Novant Health network cares for approximately 5 million patients annually at nearly 700 locations, including 15 hospitals and hundreds of outpatient facilities and physician clinics.
“COVID-19 is the most significant health threat of our generation,” said Dr. Eric Eskioglu, Executive Vice President and Chief Medical Officer for Novant Health. “We want to thank CytoDyn for partnering with us in this very important leronlimab clinical drug trial. With lives at risk, we are working together towards an effective treatment solution.”
Chump
CYDY partnership nationwide- https://www.cytodyn.com/newsroom/press-releases/detail/411/novant-health-initiates-phase-2-covid-19-trial-with
Chump
CYDY BLA filing any day. Monday is set to take up SP.
Chump
From a CYDY holder- HUGE NEWS As someone who sunk all of his savings in Leronlimab because I believed in the amazing science - and my family and friend who supported Nader and CYDY with funds to buy then PRO 140 seeing this video brings me so much gratitude!
https://losangeles.cbslocal.com/2020/04/10/coronavirus-survivor-leronlimab/
Chump
CBS Boston- Dr yang-This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria because the FDA is short staffed within that capacity. We have all verbal and email approvals to utilize Leronlimab and start the trial treating COV19 patients.
From Dr. Yang:
However, Yang said to all shorting CYDY he believes there is strong evidence to support this theory that "Leronlimab" saved her life.
“In 24 hours, she started requiring less oxygen on the ventilators, and 48 hours after that, she was able to come off the ventilator all together,” Yang said. ‘Then a couple of days after that, she didn’t require any oxygen at all.”
How Chump read it!
Wow the coverage last week- TV COVERAGE..UPDATED 4/4/20...
NY POST: Jon LevineApril 4, 2020 | 9:02am | Updated
HIV drug leronlimab, which successfully treats coronavirus, moving to phase 2 trials
https://nypost.com/2020/04/04/hiv-drug-that-treats-coronavirus-moving-to-phase-2-trials/
FOX NEWS-Dr. Daniel W. Varga on Leronlimab https://www.foxnews.com/media/coronavirus-patients-new-jersey-hydrocholoroquine-drug
KATU PORTLAND -10 OUT OF 10 OFF VENTILATORS!
CYDY/COV trial underway- UCLA - This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria because the FDA is short staffed within that capacity. We have all verbal and email approvals to utilize Leronlimab and start the trial treating COV19 patients.
From Dr. Yang:
However, Yang said to all shorting CYDY he believes there is strong evidence to support this theory that "Leronlimab" saved her life.
“In 24 hours, she started requiring less oxygen on the ventilators, and 48 hours after that, she was able to come off the ventilator all together,” Yang said. ‘Then a couple of days after that, she didn’t require any oxygen at all.”
How Chump read it!
Post#67654 was 12 years ago. Nice try. CYDY making headlines everywhere for Monday.
Chump
Here’s the story
https://losangeles.cbslocal.com/2020/04/10/coronavirus-survivor-leronlimab/
UCLA - This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria because the FDA is short staffed within that capacity. We have all verbal and email approvals to utilize Leronlimab and start the trial treating COV19 patients.
From Dr. Yang:
However, Yang said to all shorting CYDY he believes there is strong evidence to support this theory that "Leronlimab" saved her life.
“In 24 hours, she started requiring less oxygen on the ventilators, and 48 hours after that, she was able to come off the ventilator all together,” Yang said. ‘Then a couple of days after that, she didn’t require any oxygen at all.”
How Chump read it!
Bobbyinvest great post and link to CYDY- UCLA - This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria because the FDA is short staffed within that capacity. We have all verbal and email approvals to utilize Leronlimab and start the trial treating COV19 patients.
From Dr. Yang:
However, Yang said to all shorting CYDY he believes there is strong evidence to support this theory that "Leronlimab" saved her life.
“In 24 hours, she started requiring less oxygen on the ventilators, and 48 hours after that, she was able to come off the ventilator all together,” Yang said. ‘Then a couple of days after that, she didn’t require any oxygen at all.”
How Chump read it!
UCLA Dr Yang- on the news-UCLA - This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria because the FDA is short staffed within that capacity. We have all verbal and email approvals to utilize Leronlimab and start the trial treating COV19 patients.
From Dr. Yang:
However, Yang said to all shorting CYDY he believes there is strong evidence to support this theory that "Leronlimab" saved her life.
“In 24 hours, she started requiring less oxygen on the ventilators, and 48 hours after that, she was able to come off the ventilator all together,” Yang said. ‘Then a couple of days after that, she didn’t require any oxygen at all.”
How Chump read it!